Table 2.
ILK expression in different cancers
| Cancer Type | Comments | Methods | References |
|---|---|---|---|
| Prostate cancer | Overexpression of ILK in 57.1% of prostate cancer samples and 18.2% of benign prostatic hyperplasia (BPH) samples | IHC | [81] |
| Breast tumors | Greater ILK expression with increasing tumor grade | IHC | [106] |
| Colorectal cancer | Upregulated ILK mRNA and protein expression in primary CRC cells; high expression of ILK in 42.2% of primary CRC samples | IHC, WB, RT-PCR | [55] |
| ISCC | Increased expression level of ILK is associated with lymph node metastases and patient survival rate | IHC | [57] |
| CLL | ILK overexpression in patient samples, particularly in tumor cells harboring prognostic high-risk markers | IHC | [103] |
| NSCLC | Increased ILK overexpression in 46.4% of NSCLC tumors | IHC | [107] |
| Gastric cancer | ILK overexpression in 47.4% of gastric cancer tumor tissues | IHC | [108] |
| Breast cancer | Upregulated ILK1 mRNA expression in primary breast cancer tissues; 54.6% of patients are classified with ILK1 overexpression | IHC | [109] |
| Osteosarcoma | ILK overexpression is correlated with distant metastasis and it is an independent prognostic factor for poor overall survival | IHC | [47] |
| BTCC | Overexpression of ILK protein in BTCC tissue (53.6%) | IHC, RT-PCR | [110] |
| Pancreatic cancer | Increased ILK expression level in pancreatic cancer | IHC | [11] |
| CCRC | Upregulated ILK expression in high-grade CCRCs compared to low-grade CCRCs | IHC | [111] |
| RCC | ILK underexpression in normal cells and low-stage RCC cells and ILK overexpression in advanced and metastatic cells | IHC, WB | [59] |
IHC, Immunocytochemistry; WB, Western blot; RT-PCR, Real-time PCR; ISCC, laryngeal squamous cell carcinoma; CLL, Chronic Lymphocytic Leukemia; NSCLC, Non-small cell lung cancer; BTCC, Bladder transitional cell carcinoma; CCRC, Clear cell renal carcinoma; RCC, Renal Cell Carcinoma.